输卵管异位妊娠药物与手术治疗后的妊娠结局:基于人群的回顾性队列研究
该研究基于加拿大安大略省行政数据,纳入2008年1月1日至2019年12月31日期间17,090例输卵管异位妊娠患者,比较甲氨蝶呤药物治疗与手术治疗的未来活产率及复发性异位妊娠等结局。控制基线特征后,药物治疗组未来活产率(OR 1.3,95%CI 1.22-1.38,P<.001)和复发率(OR 1.17,95%CI 1.04-1.32,P<.001)均高于手术组。药物治疗失败率为15.3%,且药物治疗组总体医疗资源利用更高。
要点
- 药物治疗组未来活产率为51.6%,手术组为45.1%。
- 药物治疗组复发输卵管异位妊娠率为7.4%,手术组为6.4%。
- 药物治疗失败率为15.3%,且药物治疗组医疗资源利用更高。
核心结论
- 对于输卵管异位妊娠患者,甲氨蝶呤药物治疗相比手术治疗可能提高活产率,但代价是复发风险增加和医疗资源利用增加。
研究设计与样本
- 基于加拿大安大略省单支付方公共资助医疗系统的经验证大型行政数据集,开展基于人群的回顾性队列研究。
- 纳入2008年1月1日至2019年12月31日期间治疗的异位妊娠患者,按治疗类型(药物 vs 手术)进行比较。
- 采用标准化差异比较基线特征,并使用多变量逻辑回归分析治疗类型与结局的关联。
主要发现
- 共报告17,090例输卵管异位妊娠,其中8,204例接受药物治疗,8,737例接受手术治疗,149例接受两种治疗。
- 药物治疗组未来活产率为51.6%,手术组为45.1%;复发输卵管异位妊娠率分别为7.4%和6.4%。
- 控制基线特征后,甲氨蝶呤治疗组未来活产率(OR 1.3,95%CI 1.22-1.38,P<.001)和复发率(OR 1.17,95%CI 1.04-1.32,P<.001)均高于手术组。
- 研究期间安大略省输卵管异位妊娠发病率增加,且随时间推移更大比例患者接受药物治疗。
- 药物治疗失败率为15.3%,药物治疗组总体医疗资源利用更高。
关键数值与推荐
- 药物治疗组未来活产率51.6% vs 手术组45.1%。
- 药物治疗组复发输卵管异位妊娠率7.4% vs 手术组6.4%。
- 控制基线特征后,未来活产OR 1.3(95%CI 1.22-1.38,P<.001),复发OR 1.17(95%CI 1.04-1.32,P<.001),均为药物治疗组 vs 手术组。
- 药物治疗失败率15.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tubal ectopic pregnancy is a common cause of maternal morbidity and mortality in the first trimester. Multiple effective treatment options are available for tubal ectopic pregnancy, including medical treatment with methotrexate and surgical treatment with salpingectomy or salpingotomy. In general, medical management is preferred because it is considered less invasive and less morbid, but differences in long-term fertility and recurrence outcomes between the 2 management strategies are unclear and inconsistently reported in the literature. OBJECTIVE: This study aimed to determine future birth outcomes among patients treated medically and surgically for tubal ectopic pregnancy. Maternal morbidity, including recurrent tubal ectopic pregnancy and treatment complications, was also compared. A subanalysis was conducted comparing salpingectomy and salpingotomy for the patients treated surgically. STUDY DESIGN: This population-based retrospective cohort study used validated, large administrative data sets from Ontario, Canada's single-payer publicly funded healthcare system. Patients treated for ectopic pregnancy between January 1, 2008 and December 31, 2019 were included and compared according to type of treatment (medical vs surgical). Baseline characteristics were collected and compared using standardized differences. Multivariable logistic regression was used to determine if there was an association between treatment type and outcomes. RESULTS: A total of 17,090 cases of tubal ectopic pregnancy were reported, of which 8204 were managed medically, 8737 were managed surgically, and 149 received both treatments. Patients receiving medical management had a 51.6% future live birth rate, as opposed to 45.1% of patients who received surgical management. The recurrent tubal ectopic pregnancy rates in these groups were 7.4% and 6.4%, respectively. After controlling for baseline characteristics, the future live birth rate and the recurrence rate were higher in the group treated with methotrexate than in the surgically treated group (future live birth: odds ratio, 1.3; 95% confidence interval, 1.22-1.38; P<.001; recurrence: odds ratio, 1.17; 95% confidence interval, 1.04-1.32; P<.001). The incidence of tubal ectopic pregnancy in Ontario increased during the study period, and with time, a larger proportion of patients were treated medically. The medical management failure rate was 15.3%. Overall, healthcare utilization was higher in the group treated with methotrexate. CONCLUSION: This study demonstrates that, for patients with tubal ectopic pregnancy, medical management with methotrexate has the potential to increase live birth rates compared with surgical treatment. This comes at the cost of increased risk of tubal ectopic recurrence and increased healthcare utilization.
引用
- Rosen A, Palma L, Ordon M, et al. Pregnancy outcomes following medical vs surgical treatment of tubal ectopic pregnancy: a population-based retrospective cohort study. Am J Obstet Gynecol. 2025. PMID: 40645471. doi:10.1016/j.ajog.2025.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。